Clinical Trials Browser

Phase 1/2 × camrelizumab × 1 year × Clear all

NCT05176002 2025-11-19

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Phase 1/2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms